Promote a Clinical Trial
Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia
A study to evaluate the efficacy, safety, and pharmacokinetics of AGN-190584 when administered bilaterally, once daily for 30 days in participants with presbyopia.
Sponsored by: Allergan